Viracor Eurofins Launches Labs@HOME, a Mobile Phlebotomy Service for Post-Transplant Patient Testing

03/30/2020

Labs@HOME is a mobile phlebotomy service to aid in specimen collection for vital post-transplant testing directly from a patient’s home.

CNN - Coronavirus Test Results Across the US

03/24/2020

Viracor Eurofins said its labs are running up to 5,000 tests a day, many in 24 hours, but also said, “due to the backlog, unprecedented demand, pressures on our supply chain, and shipping delays … our turnaround time has been pushed beyond what we normally experience.

Eurofins Transplant Genomics and Viracor will Partner to Offer Remote Sample Collection Options to Support Care for Kidney Transplant Recipients During COVID-19 Outbreak

03/18/2020

Transplant Genomics, Inc. today announced that it has partnered with sister Eurofins company Viracor, and established relationships with Quest and various mobile sample collection groups, to enable patients to have samples collected remotely for analysis with our unique catalog of tests critical to monitoring health of kidney transplant recipients without requiring them to visit transplant centers.

U.S. News - Missouri Lab Develops Test for Coronavirus

03/17/2020

KCUR reports that Viracor Eurofins in Lee's Summit claims it is capable of performing more than 1,000 tests per day and returning results the same day.

Officials say the test would allow for expanding testing to patients who don't currently meet the eligibility criteria for public laboratory testing established by the Centers for Disease Control and Prevention

USA Today - News from Around the U.S.

03/17/2020

A clinical lab in the state says it has developed a test for the novel coronavirus that is more than 99% accurate. KCUR reports Viracor Eurofins in Lee’s Summit claims it is capable of performing more than 1,000 tests per day and returning results the same day.

The Kansas City Star - Coronavirus in Missouri and Kansas: Where an how to get tested, and what's changing

03/16/2020

In the Kansas City area, three national private commercial labs — Quest Diagnostics, LabCorp and Lee’s Summit-based Viracor Eurofins — are now also processing tests. You cannot go there directly. Ask your doctor’s office if they use one of these labs and what criteria they use to decide who gets tested.

NPR KCUR 89.3 - Lab In Lee’s Summit Says It Has Developed A Rapid Test For The New Coronavirus

03/16/2020

Viracor Eurofins, which was founded in 1983, says it's capable of performing more than 1,000 tests per day and returning results the same day. The test will allow clinicians to expand testing to patients who currently don't meet the eligibility criteria for public laboratory testing established by the Centers for Disease Control and Prevention.

The National Kidney Registry and Viracor Eurofins Announce Coronavirus COVID-19 Rapid Turnaround Transplant Testing for Donors and Recipients

03/16/2020

The National Kidney Registry (NKR) and Viracor Eurofins announced a partnership today to deliver testing for Coronavirus SARS-CoV-2 (the virus that causes COVID-19 disease) to NKR's vast network of Member Centers. 

KMBZ Radio Interview - What testing looks like for COVID-19

03/13/2020

Interview with Dr. Steve Kleiboeker, Viracor Coronavirus COVID-19 SARS test

KSHB 41 News - Lee's Summit Lab Testing for Coronavirus to Help Combat Spread of Virus

03/12/2020

Interview with Dr. Steve Kleiboeker

The company first became interested in developing a test for COVID-19 in December after watching what was happening in China. By the middle of January, Kleiboeker said his scientists believed they could help with the demand for test kits by developing their own in-house testing.

KMBC 9 News - Local Lab to Begin Testing for COVID-19 with Same Day Results

03/12/2020

Interview with Dr. Steve Kleiboeker

A local lab has received the green light from the Food and Drug Administration to begin testing for COVID-19 and it is able to process a thousand samples a day.

"Knowing the cause of the illness is the very first step to the most effective care," said Steve Kleiboeker, of Viracor Eurofins.

Contract PHARMA - Eurofins Offers Coronavirus Testing Services

03/12/2020

Global testing and laboratory services firm Eurofins, said two of its clinical diagnostic testing laboratories in the U.S. now offer testing for evaluation of COVID-19. On March 13, 2020, Viracor Eurofins, one of the largest infectious diseases testing laboratories in the U.S., is launching a stand-alone real time reverse transcriptase PCR assay for the qualitative detection of SARS-CoV-2.

KCTV 5 News - Local Lab May Soon Help Battle Coronavirus COVID-19

03/11/2020

Interview with Dr. Michelle Altrich

Doctors across the country are frustrated with the restricted access to COVID-19 testing.  The CDC has guidelines for which patients qualify. Those guidelines will not apply to commercial facilities like one in Lee’s Summit.

KC Business Journal - Lee's Summit Lab to Start Testing Coronavirus COVID-19

03/11/2020

Lee's Summit-based clinical specialty lab soon will start testing samples for the novel coronavirus, COVID-19. Viracor Eurofins will begin testing March 13, in accordance with the Food and Drug Administration's Emergency Use Authorization Guidance, with results in 12 to 18 hours. 

NTD Eurofins Offers Coronavirus SARS-CoV-2 Testing Through Viracor Eurofins

03/10/2020

NTD Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will offer testing for Coronavirus SARS-CoV-2 RT-PCR as of March 13, 2020 through its sister company Viracor Eurofins.  The new test utilizes real-time reverse-transcriptase polymerase chain reaction (RT-PCR) technology to detect the new coronavirus (SARS-CoV-2).  Viracor's qualitative Coronavirus SARS-CoV-2 RT-PCR assay will be tested on Nasal Swab specimens. Healthcare providers can expect results within 1-2 to days from receipt at NTD

Viracor Eurofins Launches Coronavirus (COVID-19) SARS-CoV-2 RT-PCR Test with Same Day Results (12-18 Hours)

03/10/2020

Viracor Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will start testing specimens for Coronavirus (COVID-19) SARS-CoV-2 Test RT-PCR as of March 13, 2020.

Eurofins Expands Kidney Transplant Diagnostics Offering Through Viracor TRAC™

01/08/2020

Viracor announces a donor derived cell-free DNA (dd-cfDNA) assay, Viracor TRAC™, to complement its suite of testing that supports successful outcomes for patients with kidney transplants. Viracor TRAC™ Kidney is now available to order.

Viracor Eurofins Expands Its Clinical Diagnostic Footprint to Oncology

12/13/2019

Dr. Karina Eterovic joins Viracor as the Director of Research & Development for Oncology Diagnostics for Eurofins U.S. Clinical Diagnostics group

MolDX Sets TruGraf Reimbursement Level

12/05/2019

Transplant Genomics, Inc. receives notice that the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA has set TruGraf reimbursement.

Transplant Genomics, Inc. Confirms TruGraf Will Receive Medicare Coverage Effective November 25, 2019

10/11/2019

Transplant Genomics and Viracor's innovative TruGraf ® Blood Gene Expression Test qualifies for Medicare coverage effective November 25, 2019. 

Eurofins Viracor, Inc. Responds to Patent Infringement Lawsuit By CareDx

09/26/2019

Eurofins Viracor, Inc. (“Viracor”) became aware today that CareDx has filed suit in the United States District Court for District of Delaware, alleging infringement of U.S. Patent No. 8,703,652 by three of Viracor’s tests:  Viracor TRAC™ Kidney dd-cfDNA, Viracor TRAC™ Heart dd-cfDNA and Viracor TRAC™ Lung dd-cfDNA.

Viracor Eurofins Collaborates with Northwestern University Comprehensive Transplant Center on Specialized Kidney Transplant Diagnostic

08/21/2019

Viracor Eurofins announces research collaboration with the Northwestern University Comprehensive Transplant Center, a leader in solid organ transplantation medicine in North America through high impact research and its clinical training programs. This research collaboration will further verify the novel test obtained through Eurofins’ recent acquisition of Transplant Genomics Inc. (“TGI”), and its blood gene expression test, TruGraf®.

Eurofins Expands its Transplantation Testing Footprint with the Acquisition of Transplant Genomics Inc.

06/25/2019

Eurofins Scientific (EUFI.PA), announces that it has successfully closed the acquisition of Transplant Genomics Inc. (“TGI”), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics. TGI’s innovative non-invasive tests for the management of patients with silent inflammation and rejection following kidney transplants will strengthen and complement Eurofins’ industry leading global Transplant Diagnostics offerings.

Viracor Eurofins Launches Baloxavir marboxil (XOFLUZA™) Influenza A Antiviral Resistance PCR for 2019 Flu Season

02/04/2019

Baloxavir Resistance Testing was developed for the detection of I38T/M/F mutations in H3N2 and 2009 H1N1 strains of Influenza A (flu A) to aid in the evaluation of resistance to the recent FDA approved drug. 

16S Next Generation Sequencing Bacterial Meningitis test from Viracor Eurofins provides actionable results to improve patient outcomes

12/12/2018

Healthcare professionals can detect and identify the most common bacterial pathogens
associated with meningitis, with results in 3 days

Viracor Eurofins offers first commercially available letermovir genotypic sequencing test to help healthcare professionals manage CMV

09/13/2018

Innovative Options in CMV Testing Plus Industry-Leading Turnaround Time Helps Reduce the Risk for CMV Morbidity and Mortality

Viracor Eurofins Announces Medical Advisory Board

08/21/2018

Industry-leading infectious disease and transplant physicians help Viracor ideate and innovate to serve unmet testing needs, improving patient care and outcomes

Viracor Eurofins' Algorithms Predict Risk of aGVHD and Non-relapse Mortality in Allogeneic HCT Patients

08/08/2018

New algorithms with clinically validated cutoffs aid in treatment decisions and modifications prior to or early in the disease process, to improve patient outcomes 

Eurofins Scientific Donates €1 Million to Mark its 30-Year Anniversary

10/25/2017

Eurofins Scientific (EUFI.PA) marks its 30th anniversary by donating €1 million to 40 charities selected by its global workforce.

Viracor-IBT Laboratories, Inc.’s Zika Virus RT-PCR Test Receives Emergency Use Authorization From the FDA

07/20/2016

Test Provides U.S. Physicians and Patients Same Day Results and the Option to Test Urine Alongside Blood

The National Kidney Registry Partners with Viracor-IBT Laboratories to Accelerate Living Donor Transplantation

08/13/2015

The National Kidney Registry (NKR) and Viracor-IBT Laboratories announced today a partnership to streamline pre-transplant serology testing for kidney donors.

Viracor-IBT Partners with USA Today Transplant Coverage

06/13/2014

Viracor-IBT is excited to partner with USA Today's Transplants: The Gift of Life, an annual supplement bringing attention to transplantation and the organ donation industries united work to raise awareness about gifting one's organs in order to help save the lives of others.

Published scientific study proves efficacy of ImmuKnow® test, improving patient survival rate

06/11/2015

The study demonstrated that the ImmuKnow assay provided additional data which helped optimize immunosuppression, and ultimately improve patient survival rate3.

Eurofins signs agreement to acquire Viracor-IBT Laboratories, Inc.

05/09/2014

Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, has signed a definitive agreement to acquire ViraCor-IBT Laboratories, Inc. (VIBT) from majority owner Ampersand Capital and other shareholders for approximately $255m, subject to post-closing adjustments.

Viracor-IBT Laboratories' Acquisition of the National Institute of Transplantation Enhances Testing Services for Transplant Patients.

12/10/2013

Viracor-IBT Laboratories, Inc. announced today it has closed on its previously announced transaction to purchase assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation. NIT made the decision to transfer its laboratory operations to Viracor-IBT to perpetuate the mission of its foundation, build on the legacy of its laboratory operations, and to provide testing services to more transplant patients across the U.S.

Viracor-IBT Laboratories Acquires Assets of the National Institute of Transplantation

11/13/2013

Viracor-IBT Laboratories, Inc. announced today it has signed a definitive agreement to purchase all assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation.

Viracor-IBT Laboratories Acquires Assets of Cylex™

02/05/2013

Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of CylexTM, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine. 

Viracor-IBT Laboratories Launches the First Assay to Identify a New Type of Delayed, IgE-based Allergic Reaction to Certain Meats

09/13/2010

New Alpha-Gal IgE assay is the first to specifically detect antibodies associated with a delayed-onset allergic reaction to beef, pork, and lamb, the development of which has been linked to tick bites.

Viracor-IBT Laboratories Expands Fungal Testing Services with Launch of Aspergillus PCR Panel

06/09/2010

New testing service is the first to detect and measure deadly Invasive Pulmonary Aspergillosis

Viracor-IBT Laboratories to Present at the American College of Allergy, Asthma and Immunology’s Annual Meeting

11/04/2009

Scientists from Viracor-IBT Laboratories have been selected to provide four oral presentations and one poster presentation at this year’s American College of Allergy, Asthma and Immunology’s Annual Scientific Meeting in Miami, Florida.

Viracor-IBT Laboratories Launches Comprehensive Influenza and Respiratory Virus Testing Service

08/31/2009

New suite of tests identifies 2009 Influenza A H1N1 ("swine flu"), additional influenza subtypes and other common respiratory viruses, assisting physicians in improving patient care and ensuring appropriate antiviral use.

ViraCor Laboratories and IBT Laboratories Merging to Create Unique Specialty Diagnostics Company

06/30/2009

Combined company draws on latest scientific research to provide the most accurate, reliable and comprehensive immunology and infectious disease tests available.

ViraCor Laboratories Launches Ultrasensitive JC Virus Test

05/13/2009

New test will assist in the earlier diagnosis of Progressive Multifocal Leukoencephalopathy, a serious brain infection exclusively caused by JCV.

ViraCor Laboratories Launches Fastest Available Cytomegalovirus Antiviral Resistance Test

01/15/2009

New Service Provides Comprehensive Detection of Antiviral Resistant Virus Strains in Just Three Days, Helping Physicians Treat Patients Quickly, Improve Patient Outcomes and Reduce Healthcare Costs.

ViraCor Laboratories Helps Hospitals Effectively Navigate Impending Flu Season

11/17/2008

Unique clinical reference and research lab offers complex respiratory virus testing that improves patient care by allowing doctors to identify an infection quickly and accurately.

ViraCor Laboratories Launches Comprehensive Testing for Fungal Infections

10/01/2008

Service begins with the introduction of two tests Platelia Aspergillus EIA and Fungitell β-D Glucan

ViraCor’s Founder and CEO Flip Short Named 2008 Ernst & Young Entrepreneur Of The Year® in the Central Midwest Region

06/18/2008

Award Recognizes Entrepreneurial Excellence in Life Sciences Category

ViraCor Laboratories Launches New Enterovirus Test

05/30/2008

National Clinical Reference Laboratory Provides Results in Less Than 24 Hours, Leading to Faster Diagnosis of Virus that Infects Millions of Americans Each Year

IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting

03/12/2008

Test builds on company's suite of tests to evaluate immune function

ViraCor Laboratories Is First National Reference Laboratory To Offer Novel Respiratory Viral Testing

01/04/2008

Newly-Cleared Respiratory Viral Panel Enables Clinicians to Improve Patient Care through Fast and Accurate Laboratory Diagnosis